Skip to main content
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. — Investor Relations & Filings

Ticker · ELTX ISIN · US03476J1079 US Professional, scientific and technical activities
Open in API
Filings indexed 348 across all filing types
Latest filing 2026-03-17 Regulatory Filings
Country US United States of America
Listing US ELTX

About Elicio Therapeutics, Inc.

https://elicio.com/

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).

Recent filings

Filing Released Lang Actions
EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)
Regulatory Filings
2026-03-17 English
S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Pre-Effective Amendment No. 1 to a Registration Statement on Form S-3 filed with the SEC. It includes detailed legal and procedural information about the registration of securities under the Securities Act of 1933, including indemnification provisions for directors and officers, and other regulatory compliance details. The Form S-3 is a registration statement used for securities offerings and is related to capital raising activities. This is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to capital markets and securities registration. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but a substantive filing related to financing.
2026-03-02 English
S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC by Elicio Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for public offering. The text includes details about the securities to be offered, the registration process, and legal disclaimers. It is not a financial report, earnings release, or management discussion, but a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report, so it is not RPA or RNS. Confidence is high given the clear identification as Form S-3 registration statement.
2026-02-27 English
4 Filing
Director's Dealing
2026-02-03 English
4 Filing
Director's Dealing
2026-02-03 English
4 Filing
Director's Dealing
2026-02-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.